Octreotide


Full Prescribing Info
Dosage/Direction for Use

Subcutaneous
Secretory neoplasms
Adult: Initially, 50 mcg 1-2 times daily, increased gradually to up to 600 mcg daily in 2-4 divided doses according to response. Continued treatment is not recommended if there is no benefit within a wk of starting treatment for carcinoid tumour. Initial dose may be given via IV admin of a rapid response is required.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.
Incompatibility:
Incompatible with most TPN solutions due to formation of a glycosyl octreotide conjugate, which may decrease efficacy.

Subcutaneous
Acromegaly
Adult: Initially 50 mcg tid, increased as necessary to usual dose 100-200 mcg tid. Max: 500 mcg tid.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.

Subcutaneous

Prophylaxis of complications following pancreatic surgery
Adult: 100 mcg tid of a rapid-acting preparation given for 7 consecutive days, starting at least 1 hr before operation.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.

Intravenous

Variceal haemorrhage in patients with cirrhosis
Adult: As continuous IV infusion: 25 mcg/hr for 48 hr (up to 5 days in patients at high risk of re-bleeding).
Child: ≥1 mth: 1 mcg/kg/hr (up to 50 mcg/hr); given as continuous IV infusion. Higher doses may be needed initially, reduce dose gradually over 24 hr until bleeding has stopped.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.
Incompatibility:
Incompatible with most TPN solutions due to formation of a glycosyl octreotide conjugate, which may decrease efficacy.

Subcutaneous
HIV-associated diarrhoea
Adult: Initial dose 100 mcg tid. If symptoms are not controlled after 1 wk, increase dose to 250 mcg tid, if still not effective after 1 wk stop therapy.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.

Intramuscular

Acromegaly
Adult: Following initial control with SC therapy: As a depot preparation, initially 20 mg every 4 wk. Adjust if required after 3 mth to 10-30 mg every 4 wk. Max: 40 mg every 4 wk.
Renal impairment: Dosage may need to be reduced in severe renal impairment requiring dialysis.
Special Precautions
Renal disease; risk of gall bladder disease; DM; hypothyroidism. Pregnancy, lactation, children, elderly. Monitor levels of vitamin B12 during long term therapy.
Adverse Reactions
Local pain, stinging, tingling at site of inj; anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, loose stools, steatorrhoea; biliary tract abnormalities. Hypoglycaemia and hyperglycaemia, hypothyroidism, cardiac conduction abnormalitles, pancreatitis.
Drug Interactions
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine.
Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.
Food Interaction
Schedule injections between meals to decrease adverse GI effects.
Action
Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). It also suppresses LH response to gonadotrophin-releasing hormone and reduces the secretion of gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin and pancreatic polypeptide.
Absorption: Rapidly absorbed (SC); peak plasma concentrations after 25-30 min.
Distribution: 65% plasma protein bound.
Excretion: Via urine (as unchanged); 1.5 hr (elimination half-life), prolonged in elderly.
Storage
Intramuscular: Store at 2-8°C. Stable at room temperature for up to 14 days. Intravenous: Store at 2-8°C. Stable at room temperature for up to 14 days. Subcutaneous: Store at 2-8°C. Stable at room temperature for up to 14 days.
ATC Classification
H01CB02 - octreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.
Disclaimer: This information is independently developed by CIMS based on octreotide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in